For each volunteer, specimens were removed after 2, 5, 9 and 14 days of intra-oral period.
Most of our respondents (89.4 %) reported that the extra-oral period, storage medium and injury to the PDL are factors that may affect the outcome of replantation of the avulsed tooth, which is consistent with the results of a study by Westphalen et al. [ 9].
Intra-oral periods lasted fourteen days and the volunteers were instructed to use the appliances all day long, except during meals.
Patients were followed for ∼6 months from the screening visit to the end of the oral treatment period, with efficacy assessments at screening, at every fifth infusion visit, and every 4 weeks during the oral treatment period.
Since both maraviroc and raltegravir treatments fully protected against vaginal challenge, this also confirmed that effective protective concentrations for both these drugs were reached and maintained in the vaginal tissues during the oral dosing period.
Moreover, we have also investigated the mortality and clinical signs of C57BL/6 mice throughout oral administration period.
TSS and VPT were assessed at screening, after 5, 10, 15, and 20 infusions, and every 4 weeks (±5 days) during the oral treatment period.
A sensitivity analysis was performed using a Cox Proportional Hazard model adjusting for the following confounders: age, gender, pre-period MS-related inpatient admissions, pre-period corticosteroid use (any, IV, oral), pre-period expenditures and MS severity.
Physical examination and assessment of vital signs and safety laboratory parameters were performed at screening and after the intravenous and oral treatment periods.
Quality of life was assessed by the short-form (SF -36 queSF -36aire (second version) validated in local languages (17) and was completed by patients at randomization and after the intravenous and oral treatment periods.
Estimates of gain in utility depended on the degree of symptom control that was achieved during this oral-dosing period; if symptoms were poorly controlled during this period, benefits of long-acting risperidone treatment for this population of clinically stable patients could have been overestimated.
